Moderate To Severe Plaque Psoriasis

This essay explores and reflects on the lived experiences of an elderly patient living with the long-term condition (LTC) of psoriasis. A case study is used to illustrate some of the key features of LTCs and the impact they can have on a patient’s physical, psychological and social state. It is also going to be looking at the effect some of the key features can have on a patients support network or family. In addition it will examine the nurses role in the management of LTCs and the health and social policies that may have an impact on the care received by patient with LTCs.

Psoriasis: This is a common, chronic and recurring skin disorder that changes and alters the life cycle of skin cells. It causes cells to accumulate quickly on the skin surface. The extra cells from the skin forms a thick, itchy, silvery scale and a red patch. It can appear at any part of the body such as the knee, scalp, elbow etc. it is treated with drugs applied to the skin, ingested and with ultraviolet radiation. This disease has affected about 1%-5% of the world population and it is more common to the light skinned people. Psoriasis may persist throughout a person’s life as it comes and goes but it is usually reduced during the summer period when the skin is exposed to ultraviolent radiation and flare ups are common during

The immaturity of the data is underscored by the disposition at the time of analysis. Patients were more likely to have discontinued based on adverse events than to have had disease progress or be continuing therapy. Although tolerability looked better when only patients receiving tremelimumab 1 mg were analyzed, even in that group, 30% of patients had a related grade > 3 adverse event, with 16% of patients discontinuing due to an adverse event and 4% dying from the study therapy. For comparison, in the studies that led to approval of pembrolizumab and nivolumab, grade > 3 related adverse events were seen in 7-10.5%, adverse events led to discontinuation of study therapy in 0.2-3.8% and death was related to study treatment in 0-0.3%.2, 3, 4

Jessica is a 25-year-old female who suffers from plaque psoriasis (L40.0). Her symptoms include red, itchy, thick plaques located on her arms and legs, with a 20% BSA. Jessica has tried and failed various treatments including Narrow band UVB, humira, betamethasone, derma-smooth, fluocinonide, clobetasol, hydrocortisone, and otezla, all provided her with little to no relief. Your denial states Jessica must try and fail methotrexate, however, systemic medications such as Methotrexate can cause serious problems with pregnancy and are not advised for patients; male or female, who could parent a child. Furthermore, she is not a candidate for treatment with Methotrexate due to the adverse side effects (which can be fatal) of these treatments. As

40 patients were reported to have Psoriasis (skin rash) within their peripheral extremities. The skin rash appear to be red with pus, liquid oozing from the rash (looking like a zombie rash). Each patients are also reports that their extremities itch, and sometime even inflamed.

20 patients with active RA in 1992 were first to be treated with infliximab. There was a dramatic drop in C-reactive protein (CRP and ethrocyte sedimentation rate. However patients relaped with 3-8 week demonstrating that they require another dose of

NSTE-ACS blah blah and mention statistics and other sources. This research involving current literature was conducted to determine if there is any difference in antiplatelet therapy with Plavix, when compared to Brilinta. With this knowledge, providers can be properly informed about choosing the best treatment for their patients.

Psoriasis is an extremely well-known disease of the Integumentary system that create a red, dry rash on the elbows, back, stomach, knees, palms, etc. The rash Psoriasis causes covers the infected area with dead skin cells that appear like silver scales. The disease cannot be cured, only treated, meaning that the symptoms can be agonizing to many patients with chronic forms. The scientific journal excerpt “Psoriasis Uncovered,” goes into depth about the causes, symptoms, age onset, and many more details about the disease.

“Psoriasis is a long-term (chronic) skin problem that causes skin cells to grow too quickly, resulting in thick, white silvery, or red patches of skin.” (WebMD, 2012) To uneducated individuals, they may look at a person with Psoriasis and think to stay away from them as it might be contagious. This disorder is not contagious, but it does affect a person with Psoriasis to go through social exclusion and discrimination. A mistaken trigger in the immune system is said to be the one of the causes of rapid production of skin cells in the body. Patients with Psoriasis produce new skin cells between 2-6 days. That is a little over four times less than the time they are normally produced, which is 21-28days. “Psoriasis affects approximately 3% of

If you have a friend or relative with psoriasis or any other chronic medical condition, there are things you can do to help them. They probably

Psoriasis is a skin disease and was first perceived as a distinct disease as early as 1808 [39]. The name derives from the Greek “psora” meaning “to itch” [40]. The patients suffer impaired quality of life similar to or worse than patients with other chronic diseases such as ischemic heart disease and diabetes [41]. Over the past 20 years, understanding of the disease mechanisms has most significantly and several effective development of drugs for treatments to be developed. However, we still lack a cure for this common and enigmatic disease and many patients experience significant side effects including skin cancers in non-lesional skin, abnormal renal function and liver abnormalities. It is anticipated that the identification of genes or antigens responsible for the occurrence of psoriasis will increase our understanding of its nature and make it possible to design drugs to increase patient compliance and safety and to reduce medical costs.

According to the American Academy of Dermatology, about 7.5 million Americans are currently being affected by psoriasis. Psoriasis is a disease in which cells are inflamed, causing them to vastly multiply, which then causes the skin to become red, patched, and raise above normal. Rather than taking 28-30 days to regenerate, the cells of a psoriasis patient multiplies within very few days. With this, the old, dead cells pile up, causing the redness and raise of the skin. This disease generally affects the patient’s popliteal, olecranal, palm, sole, lumbar, face, and inguinal regions. Studies show that the more surface area of the body that is covered by psoriasis, the greater the risk of death for the patient. Patients with 10% or more of

There are more than 125 million people, nearly 3% of the world’s population, who endure symptoms of psoriasis[2]. In India reported incidence of psoriasis ranges from 0.44% to 2.8% with a higher prevalence in males compared to females, with most of the patients presenting in their third or fourth decade of life [3,4,5,6]. It is a lifelong disease affecting multiple aspects of one’s life and subsequently causing significant physical

The authors made it clear that the purpose of the trial was to compare the efficacy between two treatments (daclizumab HYP and interferon beta-1a). Although the relevance of the study was clearly stated, it would have been helpful if the article mentioned that daclizumab was previously on the market with a different indication. The authors may have felt this information was not necessary to include. However, fully educating and preparing readers with information on the medications being discussed may be beneficial.

Psoriasis was copied from the Greek word psora, which means “to itch” (Jean, 2011). Psoriasis is a chronic, long lasting autoimmune skin disease that disturbs the speed of the growth cycle in skin cells (Stress-Related Disorder Sourcebook, 2016). Normal, healthy skin cells replace dead skin cells every twenty-eight to thirty days (Langley, 2005). Skin is the largest organ in the body. It protects from the environment, regulates body temperature, helps coordinate immune system regulation, function of touch sensations, waterproof, and prevents toxin substances from entering the body (Langley,2010). Psoriasis effects greater than three percent